Upper Saddle River, New Jersey, May 9, 2011— Dr. Ryan Fiorini, Founder and Chief Operating Officer, Immunologix, Inc., Charleston, South Carolina, and Barry Robins, President, DavosPharma, Upper Saddle River, New Jersey, have formed a strategic alliance whereby DavosPharma, a leading provider of discovery, chemistry and formulation services, will represent and market 100% human antibodies produced by Immunologix.
Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target any and all antigens including, but not limited to cancer, viruses, bacteria, toxins and auto-immune diseases like diabetes, lupus, rheumatoid arthritis and multiple sclerosis. This leading edge technology platform represents a paradigm shift in the way antibodies are derived, since only Immunologix can generate 100% human antibodies using their in-vitro system. Immunologix collects patient-consented explanted tonsil tissue following tonsillectomies. Immunologix captures billions of cells from each tonsil and processes them in its state of the art laboratory at the new SCRA Innovation Center in Charleston, South Carolina. The company holds a worldwide exclusive license from the Medical University of South Carolina, and exclusive U.S. and foreign patents in this technological platform.
DavosPharma was founded over 38 years ago, building an excellent reputation over the years since then in evaluating, coordinating and delivering chemistry through strategic partners. DavosPharma offers breakthrough solutions that overcome many problems that challenge both emerging pharmaceutical companies and established multinationals during drug development. The DavosPharma team includes some of the industry’s most qualified and talented chemists, pharmacists, project managers and pharmaceutical marketing experts. DavosPharma’s success in managing complex activities and timelines for exceptional pharmaceutical development is unparalleled in the industry. Its global development and manufacturing platform uses the single, best capabilities that any CRO offers. From its portfolio of CRO partners, DavosPharma can provide a fully integrated development and manufacturing capability that can be tailored to clients’ needs.
“The relationship between Immunologix and DavosPharma has been building since initial discussions began in December of 2010. We are extremely excited to partner with DavosPharma since they bring an experienced team of experts to Immunologix. Together, the companies will offer customers complete transparency. The partnership allows both parties to offer their clients a platform to 100% human monoclonal antibody ready for clinical trials. It will help in bringing our game changing technology to the pharmaceutical marketplace,” said Dr. Ryan Fiorini. “This agreement is a win-win for both companies and we are happy to team up with DavosPharma to expand our capabilities.”
Barry Robins emphasized, “The Immunologix platform of technology offers a new paradigm for therapeutic antibody discovery, development, and manufacturing. Our customers will understand that the ability to identify and produce a 100% human monoclonal antibody in less than 6 months with less adverse side effects is an extremely significant differentiator. The technology that we now offer through this strategic alliance will have an immediate impact on shorter development times, costs, and reduction of adverse effects due to immunogenicity which often derail therapeutic antibody programs. Many of our existing clients will be very interested in adopting this technology.”
Information about DavosPharma can be found at www.davos.com. More specific information about the Immunologix process is available at www.ImmunoLogix.com
Contacts:
Ryan N. Fiorini, Ph.D., MBA, MHA
Founder and COO
Immunologix, Inc.
rfiorini@immunologixinc.com
1-843-789-5904
H. Barry Robins
President
DavosPharma
hbrobins@davos.com
1-201-995-0070
For additional press information or to arrange an interview with Immunologix or DavosPharma, please contact Maria Garvey at 914-747-1400 or maria@delfino.com.
